

Keynote speaker

John Haurum, MD, PhD, board member, director and advisor



John Haurum is one of the most successful Danish biotech leaders with rich experience from leading international companies particularly within immuno-oncology. He is currently Executive Chairman of the Board at Synklino, Chairman of the Board of Agomab, and on the Board of Directors at NeoPhore, Synact Pharma ApS, and STORM Therapeutics.

John Haurum has an MD from Aarhus University and a PhD in immunology from University of Oxford. He has expertise in biological discovery, development, and manufacturing as well as innovative R&D leadership.

John Haurum was previously Chief Executive Officer of F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies that target the immune system to fight cancer. Under his leadership, F-star successfully expanded and raised €200 million in equity and non-dilutive funding.

Prior to that, John Haurum was Vice President of Research at ImClone Systems and co-founder and Chief Scientific Officer at Symphogen.